Laronib 25

Name: Laronib 25mg Capsule
Brand: Everest Pharmaceuticals Ltd.
SKU: 39526
Price: 287850 BDT
Availability: InStock
Rating: 4.9 (1 reviews)

Capsule - (25mg)

Everest Pharmaceuticals Ltd.

Generic: Larotrectinib

Out of Stock

Currently unavailable, please request or choose another variant.

৳ 287850.00
৳ 300000
4% OFF

Medicine Overview of Laronib 25mg Capsule

বাংলা

English

Indication

Indicated for treatment of patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no alternative treatments or have progressed following treatment

Administration

Capsules or oral solution may be used interchangeably

Adult Dose

Solid Tumors Indicated for treatment of patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no alternative treatments or have progressed following treatment 100 mg PO BID Continue until disease progression or until unacceptable toxicity Hepatic impairment Mild (Child-Pugh A): No dosage adjustment necessary Moderate to severe (Child-Pugh B or C): Reduce starting dose by 50%

... Show more

Child Dose

Solid Tumors Indicated for treatment of patients with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no alternative treatments or have progressed following treatment Body surface area (BSA) <1 m²: 100 mg/m² PO BID BSA >1 m²: 100 mg PO BID Continue until disease progression or until unacceptable toxicity

... Show more

Renal Dose

Renal impairment Mild to severe: No dosage adjustment necessary

... Show more

Mode of Action

Highly selective inhibitor of tropomyosin receptor kinases (TRK), TRKA, TRKB, and TRKC TRKA, B, and C are encoded by the genes NTRK1, NTRK2, and NTRK3; chromosomal rearrangements involving in-frame fusions of these genes with various partners can result in constitutively-activated chimeric TRK fusion proteins that can act as an oncogenic driver, promoting cell proliferation and survival in tumor cell lines In tumor models, larotrectinib demonstrates antitumor activity in cells by activation of TRK proteins resulting from gene fusions, deletion of a protein regulatory domain, or in cells with TRK overexpression

... Show more

Precaution

Neurologic adverse reactions (any grade) occurred; majority of neurologic adverse reactions occurred within first 3 months of treatment; advise patients not to drive or operate hazardous machinery if they are experiencing neurologic adverse reactions Increased transaminases of any grade occurred; median time to onset of increased AST/ALT was 2 months; monitor liver tests every 2 weeks during first month of treatment, then monthly thereafter, and as clinically indicated Can cause fetal harm when administered to pregnant women

... Show more

Side Effect

>10% Increased AST/ALT (45%) Anemia (42%) Fatigue (37%) Hypoalbuminemia (35%) Increased alkaline phosphatase (30%) Nausea (29%) Dizziness (28%) Vomiting (26%) Cough (26%) Constipation (23%) Neutropenia (23%) Diarrhea (22%) Pyrexia (18%) Dyspnea (18%) Peripheral edema (15%) Increased weight (15%) Headache (14%) Arthralgia (14%) Myalgia (14%) Muscular weakness (13%) Decreased appetite (13%) Abdominal pain (13%) Back pain (12%) Pain in extremity (12%) Hypertension (11%) 1-10% Nasal congestion (10%) Fall (10%) Anemia, Grade 3 or 4 (10%) Neutropenia, Grade 3 or 4 (7%) Increased weight, Grade 3 or 4 (4%) Fatigue, Grade 3 or 4 (3%) Increased alkaline phosphatase, Grade 3 or 4...

... Show more

Pregnancy Category Note

Pregnancy Based on literature reports, findings from animal studies, and its mechanism of action, embryo-fetal harm may occur when administered to a pregnant woman There are no available data on use in pregnant women Verify pregnancy status in females of reproductive potential prior to initiation Animal data Administration of larotrectinib to pregnant rats and rabbits during organogenesis resulted in malformations at maternal exposures were ~11- and 0.7-times (observed at 100 mg PO BID) Contraception Females of reproductive potential: Advise to use of effective contraception during treatment and for at least 1 week after last dose Males: Advise males with female...

... Show more

Interaction

Larotrectinib is a substrate of CYP3A4 (major); also a P-gp and BCRP substrate Larotrectinib moderately inhibits CYP3A4 Strong CYP3A4 inhibitors Coadministration with a strong CYP3A4 inhibitor may increase larotrectinib plasma concentrations and potentially result in higher incidence of adverse reactions Avoid use with strong CYP3A4 inhibitors, including grapefruit or grapefruit juice; if coadministration of strong CYP3A4 inhibitors cannot be avoided, modify dose as recommended Strong CYP3A4 inducers Coadministration with a strong CYP3A4 inducer may decrease larotrectinib plasma concentrations, which may decrease efficacy Avoid use with strong CYP3A4 inducers; if coadministration of strong CYP3A4 inducers cannot be avoided, modify dose as...

... Show more

ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন

0 People recently viewed this

Laronib 25

Capsule - (25mg)

Everest Pharmaceuticals Ltd.

Generic: Larotrectinib

Out of Stock

Currently unavailable, please request or choose another variant.

৳ 287850.00
৳ 300000
4% OFF

Disclaimer

The information provided herein is accurate, updated and complete as per the best practices of the Company. Please note that this information should not be treated as a replacement for physical medical consultation or advice. We do not guarantee the accuracy and the completeness of the information so provided. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company. We do not take any responsibility for the consequences arising out of the aforementioned information and strongly recommend you for a physical consultation in case of any queries or doubts.